Glaukos Q4 net sales $71.2M, down 3% YoY; full-year net loss $99.2M; guides 2023 sales $290-295M

GLAUKOS Corp

2022-FY EPS reported -$2.09 revenue$282,862,000

Q4 net sales $71.2M (-3% YoY); glaucoma $52.9M, corneal health $18.3M.
Q4 GAAP net loss $31.5M ($0.66/sh); non-GAAP net loss $25.1M ($0.53/sh).
Full-year 2022 net sales $282.9M (-4% YoY); net loss $99.2M ($2.09/sh).
2023 net sales guidance $290M-$295M; cash & equivalents $360M.
R&D expenses rose 34% in Q4 to $35.8M; SG&A up 9% to $51.9M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GLAUKOS Corp reported fiscal year 2023 results: revenue $290 million to $295 million. Guidance initiated.

Period: fiscal year 2023
Revenue: $290 million to $295 million
Guidance: initiated
Result: guidance update

Exact text from the filing

The company expects 2023 net sales to be in the range of $290 million to $295 million based on the latest foreign currency exchange rates.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GLAUKOS Corp reported fourth quarter ended December 31, 2022 results: revenue $71.2 million, net income $31.5 million, EPS ($0.66) per diluted share.

Period: fourth quarter ended December 31, 2022
Revenue: $71.2 million
Net income: $31.5 million
EPS: ($0.66) per diluted share
Result: reported results

Exact text from the filing

Net sales in the fourth quarter of 2022 of $71.2 million declined 3% on a reported basis, or were flat on a constant currency basis, compared to $73.2 million in the same period in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GLAUKOS Corp reported fiscal year ended December 31, 2022 results: revenue $282.9 million, net income $99.2 million, EPS ($2.09) per diluted share.

Period: fiscal year ended December 31, 2022
Revenue: $282.9 million
Net income: $99.2 million
EPS: ($2.09) per diluted share
Result: reported results

Exact text from the filing

Net sales in 2022 of $282.9 million declined 4% on a reported basis, or 2% on a constant currency basis, compared to $294.0 million in 2021.

View on SEC.gov

Browse all earnings releases →

GLAUKOS Corp filing history →

Source: SEC EDGAR

accession 0001558370-23-001767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.